The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Table 6 Multivariate analysis of risk factors for overall survival

Factor	Multivariate analysis
Factor	HR	95% CI	P
Male	1.423	0.481–4.210	0.524
TACE + sorafenib versus sorafenib	0.498	0.278–0.892	0.019
Age	0.984	0.963–1.005	0.140
Tumor number	1.286	1.031–1.604	0.026
Tumor diameter (cm)	1.031	0.965–1.101	0.367
No vascular invasion	0.354	0.183–0.685	0.002
Metastasis	1.365	0.784–2.375	0.271
Child-Pugh stage A	0.308	0.141–0.674	0.003
AFP < 400 ng/mL	0.648	0.373–1.124	0.123

ISSN: 1471-2407